NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 56 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2018 | $5,000 | -54.5% | 47,698 | +2.1% | 0.00% | – |
Q3 2018 | $11,000 | 0.0% | 46,701 | +54.8% | 0.00% | – |
Q1 2018 | $11,000 | -67.6% | 30,165 | -68.6% | 0.00% | – |
Q4 2017 | $34,000 | -58.0% | 95,985 | -50.9% | 0.00% | – |
Q3 2017 | $81,000 | +6.6% | 195,631 | +31.5% | 0.00% | – |
Q2 2017 | $76,000 | +153.3% | 148,764 | +182.7% | 0.00% | – |
Q1 2017 | $30,000 | +150.0% | 52,624 | +185.7% | 0.00% | – |
Q4 2016 | $12,000 | -78.9% | 18,421 | -70.4% | 0.00% | – |
Q3 2016 | $57,000 | -51.7% | 62,175 | -72.1% | 0.00% | -100.0% |
Q2 2016 | $118,000 | -15.7% | 222,880 | +50.9% | 0.00% | 0.0% |
Q1 2016 | $140,000 | -48.1% | 147,749 | -27.2% | 0.00% | -50.0% |
Q4 2015 | $270,000 | -80.7% | 202,967 | -66.9% | 0.00% | -77.8% |
Q3 2015 | $1,399,000 | +3008.9% | 613,402 | +2466.1% | 0.01% | – |
Q4 2014 | $45,000 | +7.1% | 23,904 | -15.0% | 0.00% | -100.0% |
Q2 2014 | $42,000 | – | 28,119 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Platinum Management (NY) LLC | 15,046,431 | $19,861,000 | 4.55% |
COMMERZBANK AKTIENGESELLSCHAFT /FI | 6,702,002 | $8,847,000 | 0.04% |
LifePlan Financial Group, Inc | 28,810 | $38,000 | 0.03% |
Hudock, Inc. | 27,500 | $36,000 | 0.02% |
NOMURA HOLDINGS INC | 4,631,059 | $6,250,000 | 0.02% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 491,780 | $649,000 | 0.02% |
Stratos Wealth Partners, LTD. | 45,535 | $60,000 | 0.01% |
LYNCH & ASSOCIATES/IN | 18,000 | $24,000 | 0.01% |
Tower Research Capital LLC (TRC) | 71,463 | $94,000 | 0.01% |
SII INVESTMENTS INC/WI | 63,115 | $83,000 | 0.01% |